Inspired by this point, we analysed the inflammation in TIOs+NIR1 treated mice, as shown, compared with TIOs+NIR3 treatment, the IL-1β, IL-18 and HMGB-1 release in tumour beds were almost four fifths lower (Supplementary Fig. 17a, c). The gene discussed is HMGB1; the disease is neoplasm.